Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHZUF8)

Drug Name

AGN-208397 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Retina venous occlusion	9B74.1	Phase 1/2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Erbb2 tyrosine kinase receptor (HER2)	DTT	ERBB2	6.226	7.169	7.196	6.397

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Retina venous occlusion

ICD Disease Classification

9B74.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Erbb2 tyrosine kinase receptor (HER2)	DTT	ERBB2	5.67E-03	-1.26	-2.05

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01027650) Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO). U.S. National Institutes of Health.
2	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.